Organon & Co. (OGN) stock analysis

In our weekly check, Organon & Co. is graded C (A to F). Of 25 checks on debt, profit, cash flow and trend: 12 pass, warnings: 6, red flags: 7.

Sector: Healthcare · Drug Manufacturers—General

Strengths

Warning signs

Next earnings report: 2026-11-09

Similar companies

BIIB · ALVO · AUPH · GRDN · HRMY · MD

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-10

Open the full analysis